Skip to main content
OpenTrials
Completed

NCT Number: NCT04727775

Antiviral Drugs on the Treatment of SARS-CoV-2

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Complication of Medical Care Infections Lung Diseases Pneumonia Pneumonia, Viral Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aidos Konkaev, Astana, Kazakhstan

Loading trial locations.

About this study

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

main group

  • Patients with COVID19 with medium and easy condition disease
  • take favipiravir/remdisivir control group
  • Patients with COVID19 with medium and easy condition disease
  • not take favipiravir/remdisivir

Exclusion criteria

  • patients younger 18
  • severe conditionis

Treatment and study plan

Favipiravir

Drug

Antiviral drugs

Remdesivir

Drug

Antiviral drugs

Primary outcomes

  1. Outcome without comlications

    Time frame: 14 days

    The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2

Secondary outcomes

  1. Heart rate

    Time frame: 14 days

    Measure

  2. SpO2

    Time frame: 14 days

    Measure

  3. Blood pressure

    Time frame: 14 days

    Measure

  4. Respiratory rate

    Time frame: 14 days

    Measure

Sponsors and collaborators

Lead sponsor

Astana Medical University

Other

Registry information

Official study title

A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19

Acronym: FavRem

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jan 27, 2021
Registry last updated
Aug 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.